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ABSTRACT. A novel series of 1,3,4-oxadiazole containing sulfonamide derivatives were synthesized by 5-(5-
cyclohexyl-1,3,4-oxadiazol-2-yl)-2-methyl-benzenesulfonyl chloride. A good yield of intermediate with various 
substituted like aryl/hetero was formed. All the synthesized compounds were characterized by FT-IR, 1H NMR, 
13C NMR and mass spectral studies. These compounds were evaluated for their preliminary bioassay in vitro 
antimicrobial activity, anti-inflammatory and anti-diabetic activities. In this series, most of the compounds have 
good anti-inflammatory activity. Particularly, compounds 5c, 5d and 5e showed excellent anti-inflammatory 
activity with IC50 values of 110, 110, and 111 μg/mL than diclofenac (157 μg/mL). The frontier orbital energy and 
the global reactivity descriptor were discussed for the tested compounds using RB3LYP/311G(d,p) basis set. 
Results revealed that the theoretical calculations of antimicrobial activity were closely related to quantum 
chemical parameters. 
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INTRODUCTION 
Sulfonamides are one of the important drugs in medicinal chemistry, which are effective 
chemotherapeutic agents against microbial infection in human beings [1]. They are 
bacteriostatic in nature and block the biosynthesis of coenzyme (folate) resulting in the arrest of 
bacterial growth and cell division. Sulfonamide derivatives has been well known for their 
antitumor [2], anti-diabetic [3], anti-malarial [4], antimicrobial [5-6], anti-inflammatory [7], 
antioxidant [8], COX inhibitors [9], lipoxygenase inhibitors [10], alzheimer’s disease [11], etc. 
Many literature survey revealed that 1,3,4-oxadiazole possess diverse pharmacological activities 
such as anticancer [12-14], antimicrobial [15-18], anti-HIV [19], antiproliferative [20], antiviral 
[21], anti-inflammatory [22-23], anticonvulsant [24]. Some of 2,5-disubstituted 1,3,4- 
oxadiazole based entities have emerged as most potent antimicrobial activities.  
Nowadays, many microorganisms are resistant to antibiotics. Therefore, it is essential to find       
a new and better multi drug. Similarly, bio nanomedicines are considered as one of the most 
promising technique. It is successfully implicated as a drug delivery system in the treatment of 
various diseases like antimicrobial [25-27], anticancer [28-29], anti-inflammatory [30], antivirus 
[31], etc. 
In this paper, we have synthesized new 1,3,4-oxadiazole derivatives with sulfonamide and 
tested for in vitro antimicrobial, antidiabetic, and anti-inflammatory activities. Some principal 
quantum descriptors have been correlated with the antimicrobial activity of the synthesized 
compounds.  
                                                         EXPERIMENTAL 
General 
The reagents and chemicals used in the study were available commercially. All the reactions 
were monitored by silica coated TLC plates. Solvents (ethyl acetate:petroleum ether) were used 
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as mobile phase. Melting points are uncorrected and checked by an electro thermal apparatus. 
FT-IR spectrums of synthesized compounds were recorded in the range of 4000-400 cm-1 using 
a Perkin-Elmer RX I spectrometer with KBr pellet. Bruker 300 and 400 MHz NMR 
spectrometers (AVANCE II) were used to record H1 NMR, 13C NMR spectra and CDCl3 is used 
as a solvent. The molecular mass of the compounds was confirmed by using thermo lcq Deca 
XP MAX spectrometer. Elemental analyses were also performed to calculate the amount of C, 
H, and N using Perkin–Elmer 2400 analyzer. 
 
Synthesis of 2-cyclohexyl-5-p-tolyl-1,3,4-oxadiazole  
 
Toulic hydrazide (1 mmol) and cyclohexanoic acid (1 mmol) in phosphorous oxychloride (7 
vol) were refluxed for 2-3 h at 110 oC. The reaction progress was monitored on thin layer 
chromatography by using petroleum ether and ethyl acetate (7:3) as mobile phase and it was 
visualized in UV light. After completion of the reaction, the residue was allowed at room 
temperature and slowly poured into crushed ice with constant stirring. The solid was filtered off, 
washed with water repeatedly and dried, that afforded white solid as product. Yield 80%. m.p. 
92 oC. FT-IR (KBr) in cm-1: 1494, 1442 and 1411 (for oxadiazole), 1593 (C=N), 1016 (C-O-C), 
2932, 2856 (CH2 Str). 
1H NMR (CDCl3 300 MHz) δ ppm: 1.26-1.49 (m, 3H), 1.61-1.79 (m, 3H), 
1.85-1.93 (m, 2H), 2.13-2.19 (m, 2H), 2.45(s, 3H), 2.91-3.03 (m, 1H), 7.33 (d, 2H, J = 7.8 Hz), 
7.91 (d, 2H, J = 8.1 Hz). 13C NMR (CDCl3, 300 MHz) δ ppm: 168.5, 163.2, 140.8, 128.9, 125.8, 
128.2, 120.4, 41.8, 39.2, 38.5, 34.2, and 29.2. LC/ESI: m/z value 243 (M+1). Anal. calc. for 
C15H18N2O (242): C, 74.4; H, 7.43; N, 11.56; O, 6.60. Found: C, 74.3; H, 7.32; N, 9.58; O, 6.62. 
 
Synthesis of 5-(5-cyclohexyl-1,3,4 oxadiazol-2-yl)-2-methyl-benzenesulfonyl chloride  
 
Chlorosulphonic acid (5 vol) was added to 2-cyclohexyl-5-p-tolyl-1, 3,4-oxadiazole (1 mmol) at 
0 oC. Then, the mixture was refluxed at 110 oC for 3 h. The progress of the reaction was checked 
by TLC by petroleum ether and ethyl acetate (8:2) as mobile phase and was visualized in UV 
light chamber. The product was cooled at room temperature and poured into crushed ice slowly. 
The mixture was extracted with ethyl acetate, water, brine water and dried with anhydrous 
Na2SO4. The organic layer was concentrated under reduced pressure and finally the product was 
washed with petroleum ether to got afforded dirty white solid. Yield 68%; m.p. 112 oC. FT-IR 
(KBr) in cm-1: 2932, 2856 (CH2 Str), 1485 (C=C), 1593 (C=N), 1335 (SO2 str assym), 1160 (SO2 
str sym), 1018 (C-O-C). 1H NMR (CDCl3 300 MHz) δ ppm: 1.36-1.56 (m, 4H), 1.64-1.71 (m, 
4H), 2.13-2.18 (d, 2H), 2.92 (s, 3H), 2.93-3.07 (m, 1H), 7.59 (d, 1H, J = 8.1 Hz), 8.33 (dd, 1H,  
J = 7.8 Hz), 8.75 (s, 1H). 13C NMR (CDCl3   300 MHz) δ ppm: 170.6, 163.0, 140.1, 133.6, 127.8, 
122.6, 118.8, 108.2, 35.3, 31.9, 29.7, 25.3, and 20.6. LC/ESI: m/z value 341 (M+1). Anal calc. 
for C15H17ClN2O3 S (340): C, 52.86; H, 5.03; N, 8.22; O, 14.08. Found: C, 52.76; H, 5.02; N, 
8.24; O, 14.12. 
 
Synthesis of 1,3,4-oxadiazole-sulfonamide derivatives  
 
The suitable amine (1 equiv), pyridine (4 equiv) were dissolved in dichloro methane and 1,3,4-
oxdiazole-sulfonyl chloride derivative (1.2 equiv) was added in  drop wise at -2 oC to -7 oC. The 
organic reaction mixture was stirred at the room temperature for 2-4 h. After completion of the 
reaction, the reaction mixture was poured into ice water and was diluted with ethyl acetate, and 
washed with water, 2 M hydrochloric acid, 10% sodium bicarbonate, brine water and dried with 
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5-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-N-(3-fluoro-phenyl)-2-methyl-benzenesulfonamide (5a). 
Yield 61%; m.p. 187 oC. FTIR (KBr) in cm-1: 3120 (NH), 2935, 2859 (CH2 str), 1606 (C=N), 
1488 (C=C), 1336 (SO2 str assym), 1167 (SO2 str sym), 1070 (C-O-C), C-F (1270). 
1H NMR 
(CDCl3 ,300 MHz) δ: 1.30-1.45 (m, 5H), 1.66-1.79 (m, 2H), 1.87-1.91 (m, 2H), 2.13-2.16 (d, 
2H), 2.71 (s, 3H), 6.63-6.73 (m, 2H), 6.95 (s, 1H), 7.10-7.17 (m, 2H), 7.44 (d, 1H, J = 8.1 Hz), 
8.13 (dd, 1H, J = 7.8 Hz), 8.59 (s,1H). 13C NMR (300 MHz, CDCl3) δ ppm: 170.6, 163.05, 
161.4, 140.9, 138.6, 133.6, 130.7, 127.8, 122.6, 116.1, 111.8, 107.9, 35.3, 31.9, 29.7, 25.3, 20.6. 
LC/ESI-MS: m/z value; 416 (M+1). Anal calc. for C21H22FN3O3S (415): C, 60.71; H, 5.34; N, 
10.11; O, 11.55. Found: C, 60.51; H, 5.26; N, 9.57; O, 11.38.  
 
5-(5-Cyclohexyl-[1,3,4]-oxadiazol-2-yl)-2-methyl-N-p-tolyl-benzenesulfonamide (5b). Yield 
65%; m.p. 119 oC. FTIR (KBr) in cm-1: 3122 (NH), 2931, 2856 (CH2 str), 1577 (C=N), 1512 
(C=C), 1333 (SO2 str assym), 1158 (SO2 str sym), 1018(C-O-C). 
1H NMR (CDCl3, 300 MHz): 
1.20-1.51 (m, 1H), 1.60-1.78 (m, 2H), 1.85-1.9 (m, 2H), 2.10-2.15 (m, 2H), 2.21 (s, 3H), 2.69 
(s, 3H), 2.94-3.02 (m, 1H), 7.01-7.06 (m, 1H), 7.40 (t, 1H, J = 8.1 Hz), 8.14 (d, 1H, J = 8.0 Hz), 
8.54 (s,1H), 9.82 (s, 1H). 13C NMR (100 MHz, CDCl3) δ ppm: 170.3, 163.5, 160.1, 141.1, 138.6, 
136.8, 133.1, 130.7, 129.8, 122.7, 122.3, 112.8, 110.9, 105.9, 35.3, 30.1, 25.7, 25.3 21.3, 20.7. 
LC/ESI-MS: m/z value; 412 (M+1). Anal calc. for C22H25N3O3S (411): C, 64.21; H, 6.12;  N, 
10.21; O, 11.66. Found: C, 64.01; H, 5.96; N, 9.87; O, 11.33. 
  
5-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-N-(3-methoxy-phenyl)-2-methyl-benzenesulfonamide 
(5c). Yield 58%; m.p. 126 oC. FTIR (KBr) in cm-1: 3128 (NH), 2936, 2850 (CH2 str), 1569 
(C=N), 1522 (C=C), 1337 (SO2 str assym), 1160 (SO2 str sym), 1040 (C-O-C).
 1H NMR (CDCl3, 
300 MHz): 1.27-1.39 (m, 4H), 1.66-1.79 (m, 2H), 1.87-1.91 (m, 2H), 2.13-2.16 (d, 2H), 2.71 (s, 
3H), 2.96-3.04 (m, 1H), 3.73 (s, 3H), 6.63-6.73 (m, 2H), 6.95 (s, 1H), 7.10-7.17 (m, 2H), 7.44 
(d, 1H, J = 8.1 Hz), 8.13 (dd, 1H, J = 7.8 Hz), 8.59 (s, 1H ). 13C NMR (300 MHz, CDCl3) δ 
ppm: 170.5, 163.0, 160.3, 140.9, 138.7, 137.2, 133.5, 130.8, 130.2, 122.9, 122.5, 112.9, 110.9, 
106.9, 55.3, 35.3, 30.1, 25.3, 20.8, 20.6. LC/ESI-MS: m/z value; 428 (M+1). Anal calc. for 
C22H25N3O4S (427): C, 61.81; H, 5.81; N, 9.83; O, 14.97. Found C: 61.62; H, 5.76; N, 9.77; O, 
14.39.  
 
N-(4-Chloro-phenyl)-5-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-methyl-benzenesulfonamide   
(5d). Yield 63%; m.p. 161 oC. FTIR (KBr) in cm-1: 3141 (NH), 2956, 2862 (CH2 str), 1568 
(C=N), 1478 (C=C), 1332 (SO2 str assym), 1165 (SO2 str sym), 1025 (C-O-C), 745 (C-Cl).
 1H 
NMR (CDCl3, 300 MHz): 1.19-1.31 (m, 1H ), 1.38-1.50 (m, 3H), 1.61-1.78 (m, 2H), 1.86-1.91 
(m, 2H), 2.11-2.16 (m, 2H), 2.73 (s, 3H), 2.95-3.02 (m, 1H), 6.99-7.02 (m, 1H), 7.16-7.22 (m, 
2H), 7.30 (d, 1H, J = 1.5 Hz), 7.43 (d, 1H. J = 7.8 Hz), 7.55 (dd, 1H, J = 8 Hz), 8.14 (dd, 1H, J 
= 8.1Hz), 8.63 (s, 1H). 13C NMR (100 MHz, CDCl3) δ ppm: 170.4, 163.1, 140.9, 138.9, 135.6, 
133.4, 130.7, 129.8, 128.9, 128.1, 127.2, 122.1, 35.3, 30.1, 29.3, 25.4, 20.6. LC/ESI-MS: m/z 
value; 433(M+1). Anal calc. for C21H22ClN3O3S (427): C, 58.39; H 5.13, N 9.73, O 11.11. 
Found C 58.32, H 5.16, N 9.78, O 11.21. 
 
N-(4-Bromo-phenyl)-5-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-methyl-benzene sulfonamide (5e).  
Yield 72%; m.p. 156 oC. FTIR (KBr) in cm-1: 3106 (NH), 2927, 2854 (CH2 str), 1575 (C=N), 
1484 (C=C), 1336 (SO2 str assym), 1159 (SO2 str sym), 1069 (C-O-C), 590 (C-Br).
 1H NMR 
(CDCl3, 300 MHz): 1.31-1.49 (m, 3H), 1.61-1.79 (m, 3H), 1.86-1.91 (m, 2H), 2.11-2.16 (m, 
2H), 2.68 (s, 3H), 2.95-3.03 (m, 1H ), 6.99-7.05 (m, 2H), 7.33-7.37 (m, 2H), 7.49 (d, 1H, J = 8.1 
Hz),7.54 (s, 1H), 8.11 (dd, 1H, J = 8.1 Hz). 13C NMR (300 MHz, CDCl3) δ ppm: 170.5, 163.0, 
141.7, 140.9, 138.7, 135.4, 133.5, 132.4, 130.8, 127.8, 122.6, 118.5, 35.3, 30.1, 25.3, 20.6, 15.2. 
LC/ESI-MS: m/z value; 477 (M+1). Anal calc. for C21H22 BrN3O3S (476): C 52.95, H 4.65, N 
8.82, O 10.08. Found C 51.83, H 4.60, N 8.85, O 10.12. 
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5-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-methyl-N-(3-nitro-phenyl)-benzenesulfonamide (5f). 
Yield 56%; m.p. 118 oC. FTIR (KBr) in cm-1: 3120 (NH), 2929, 2855 (CH2 str), 1617 (C=N), 
1481 (C=C), 1360 (SO2 str assym), 1160 (SO2 str sym), 1090 (C-O-C), 1530 (C-NO2).
 1H NMR 
(CDCl3, 300 MHz): 1.34-1.46 (m, 4H), 1.68-1.77 (m, 2H), 1.87-1.90 (m, 2H), 2.12-2.15 (d, 2H), 
2.74 (s, 3H), 2.97-3.02 (m, 1H), 7.34-7.43 (m, 2H), 7.52 (d, 1H, J = 6.0 Hz ), 7.84 (d, 1H, J = 
6.3 Hz), 8.03 (s, 1H), 8.12 (d, 1H, J = 6.0 Hz), 8.63 (s, 1H), 9.93 (s, 1H). 13C NMR (300 MHz, 
CDCl3) δ ppm: 169.6, 163.4, 141.5, 140.6, 138.7, 130.9, 130.1, 127.8, 122.3, 118.6, 36.2, 30.6, 
25.1, 20.5, 14.3. LC/ESI-MS: m/z value; 443 (M+1). Anal calc. for C21H22 N4O5S (442): C 57, H 
5.01, N 12.66, O 10.08. Found C 57.2, H 5.72, N 9.79, O 14.35. 
 
5-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-N-(3,5-difluoro-phenyl)-2-methyl-benzene sulfonamide 
(5g). Yield 71%; m.p. 198 oC. FTIR (KBr) in cm-1: 3094 (NH), 2934, 2859 (CH2 str), 1618 
(C=N), 1479 (C=C), 1339 (SO2 str assym), 1172 (SO2 str sym), 1024 (C-O-C), 997 (C-F).
 1H 
NMR (CDCl3, 300 MHz): 1.30-1.51 (m, 4H), 1.61-1.78 (d, 2H), 1.86-1.90 (m, 2H), 2.12-2.17 
(dd, 2H), 2.95-3.03 (m, 1H), 2.71 (s, 3H), 6.48-6.55 (m, 1H), 6.71-6.77 (m, 3H), 7.45 (d, 1H, J 
= 8.1 Hz), 8.13 (dd, 1H, J = 7.95 Hz). 13C NMR (300 MHz, CDCl3) δ ppm: 170.4, 164.5, 161.9, 
138.5, 137.9, 128.7, 125.7, 124.1, 122.8, 118.7, 107.2, 35.2, 30.1, 25.7, 25.3, 14.6.LC/ESI-MS: 
m/z value; 434 (M+1). Anal calc. for C21H21F2N3O3S (433): C 58.19, H 4.88, N 9.69, O 11.07. 
Found C 58.32, H 4.78, N 9.72, O 11.13. 
 
5-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-methyl-N-naphthalen-2-yl-benzenesulfonamide (5h). 
Yield 69%; m.p. 172 oC. FTIR (KBr) in cm-1: 3053 (NH), 2945, 2856 (CH2 str), 1584 (C=N), 
1549 (C=C), 1337 (SO2 str assym), 1161 (SO2 str sym), 1088 (C-O-C),
 1H NMR ( CDCl3, 300 
MHz) δ ppm: 1.37-1.47 (m, 3H), 1.69-1.76 (m, 2H), 1.83-1.88 (m, 2H), 2.04-2.11 (m, 2H), 2.63 
(s, 3H), 2.88-2.94 (m, 1H), 7.03 (s, 1H ), 7.25 (d, 1H, J = 6.6 Hz ), 7.32 (t, 1H, J = 7.8 Hz),7.40 
(d, 1H, J = 8.1 Hz), 7.46-7.53 (m, 2H), 7.73 (d, 1H, J = 8.4 Hz ), 7.80-7.85 (m, 1H), 7.93-7.97 
(m, 1H), 8.14 (d, 1H, J = 7.8 Hz), 8.49 (s, 1H). 13C NMR (300 MHz, CDCl3) δ ppm: 170.4, 
163.0, 140.9, 139.1, 134.3, 133.4, 131.0, 130.9, 130.8, 129.2, 128.9, 127.8, 126.9, 126.5, 125.4, 
123.1, 122.7, 121.5, 35.2, 30.1, 25.3, 20.9, 14.2. LC/ESI-MS: m/z value; 448 (M+1). Anal calc. 
for C25H25N3O3S (447): C 67.09, H 5.63, N 9.39, O 10.72. Found C 67.12, H 5.71, N 9.43, O 
10.83. 
 
5-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-methyl-N-pyridin-2-yl-benzene sulphonamide (5i). 
Yield 65%; m.p. 156 oC. FTIR (KBr) in cm-1: 3053 (NH), 2923, 2853 (CH2 str), 1598 (C=N), 
1552 (C=C), 1334 (SO2 str assym), 1162 (SO2 str sym), 1035 (C-O-C),
 1H NMR (CDCl3, 300 
MHz) δ ppm: 1.36-1.52 (m, 4H), 1.64-1.79 (m, 2H), 1.88-1.92 (m, 2H), 2.13-2.18 (d, 2H), 2.69 
(s, 3H), 2.96-3.06 (m, 1H), 6.77-6.82 (m, 1H), 7.35 (d, 1H, J = 9 Hz), 7.40 (d, 1H, J = 8.1 Hz), 
7.66-7.72 (m, 1H), 8.09 (d, 1H, J = 7.8 Hz), 8.31 (dd, 1H, J = 6 Hz), 8.78 (s, 1H), 13.9 (s, 1H). 
13C NMR (100 MHz, CDCl3) δ ppm: 170.4, 163.4, 155.7, 143.3, 141.2, 140.7, 138.7, 133.3, 
130, 127.1, 122.3, 115.8, 113.3, 35.3, 30.2, 25.4, 20.7, 15.3. LC/ESI-MS: m/z value; 399 (M+1). 
Anal calc. for C20H22N4O3S (398): C 60.28, H 5.56, N 14.06, O 12.05. Found C 60.42, H 5.57, N 
14.09, O 12.10. 
 
1-[5-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-methyl-benzenesulfonyl]-2,3-dihydro-1H-indole 
(5j). Yield 59%; m.p. 98 oC. FTIR (KBr) in cm-1: 2932, 2853 (CH2 str), 1600 (C=N), 1473 
(C=C), 1327 (SO2 str assym), 1160 (SO2 str sym), 1028 (C-O-C).
 1H NMR (CDCl3, 300 MHz) δ 
ppm: 1.36-1.52 (m, 4H), 1.62-1.71 (m, 4H), 2.13-2.18 (d, 2H), 2.65 (s, 3H), 2.93-3.10 (m, 1H), 
3.12-3.15 (m, 2H), 4.02-4.10 (m, 2H), 6.98 (t, 2H, J = 7.2 Hz), 7.07-7.18 (m, 1H), 7.41 (d, 1H, J 
= 8.0 Hz), 7.46 (d, 1H, J = 7.6 Hz), 8.11( d, 1H,  J = 8 Hz), 8.49( s, 1H ). 13C NMR (300 MHz, 
CDCl3) δ ppm: 170.2, 162.8, 141.9, 138.5, 133.7, 131.1, 130.5, 128.9, 127.6, 127.0, 125.3, 
123.7, 122.5, 114.4, 49.8, 39.8, 35.1, 30.0, 27.8, 25.2, 20.7. LC/ESI-MS: m/z value; 424 (M+1). 
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Anal calc. for C23H25N3O3S (423): C 65.23, H 5.95, N 9.92, O 11.33. Found C 65.32, H 5.96, N 
9.94, O 11.39. 
 
1-[5-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-methyl-benzenesulfonyl]-6-nitro-2,3-dihydro-1H-
indole (5k). Yield 56%; m.p. 120 oC. FTIR (KBr) in cm-1: 2934, 2855 (CH2 str), 1597 (C=N), 
1477 (C=C), 1344 (SO2 str assym), 1167 (SO2 str sym), 1077 (C-O-C), 1522 (C-NO2).
 1H NMR 
(CDCl3, 300 MHz) δ ppm: 1.36-1.48 (m, 2H), 1.61-1.74 (m, 2H), 1.86-1.89 (m, 2H), 2.10-2.14 
(d, 2H), 2.67 (s, 3H), 2.96-3.02 (m, 1H), 7.26-7.30 (m, 1H), 7.46-7.49 (m, 1H), 7.89 (d, 1H, J = 
6.8 Hz), 8.14 (d, 1H, J = 7.6 Hz), 8.27 (t, 1H, J = 7.6 Hz), 8.50 (s, 1H). 13C NMR (300 MHz, 
CDCl3) δ ppm: 170.5, 162.9, 141.7, 138.2, 133.8, 131.1, 130.4, 128.2, 127.1, 127.0, 125.4, 
123.7, 119.1, 109.1, 50.3, 40.2, 35.3, 30.2, 27.9, 25.3, 20.9. LC/ESI-MS: m/z value; 469 (M+1). 
Anal calc. for C23H24N4O5S (468): C 58.96, H 5.16, N  11.96, O 17.07 Found C 58.92, H 5.19, N 
11.86, O 17.13.  
 
1-[5-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-methyl-benzenesulfonyl]-1H-indole (5l). Yield 
58%; m.p. 98 oC. FTIR (KBr) in cm-1: 2930, 2859 (CH2 str), 1579 (C=N), 1471 (C=C), 1320 
(SO2 str assym), 1162 (SO2 str sym), 1048 (C-O-C).
 1H NMR (CDCl3, 300 MHz) δ ppm: 1.38-
1.49 (m, 2H), 1.56-1.65 (m, 2H), 1.76-1.86 (m, 4H), 2.06-2.16 (d, 2H), 2.56 (s, 3H), 2.91-3.13 
(m, 1H), 6.89 (d, 1H, J = 7.2 Hz ), 7.07-7.18 (m, 3H), 7.26 (d, 1H, J = 8.0 Hz ), 7.36 (d, 1H, J = 
7.6 Hz), 7.65 (d, 1H, J = 7.8 Hz), 8.11 (d, 1H, J = 8 Hz), 8.49 (s, 1H). 13C NMR (300 MHz, 
CDCl3) δ ppm: 168.2, 163.8, 141.6, 139.5, 136.5, 131.3, 130.6, 128.7, 127.1, 124.6, 121.8, 
120.3, 119.4, 111.2, 109.5, 102.6, 34.7, 30.2, 27.7, 25.4, 20.2. LC/ESI-MS: m/z value; 422 
(M+1). Anal calc. for C23H23N3O3S (421): C 65.5, H 5.50, N 9.97, O 11.39. Found C 65.42, H 
5.47, N 9.96, O 11.38. 
 
4-[5-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-methyl-benzenesulfonyl]-morpholine  (5m). Yield 
60%; m.p. 98 oC. FTIR (KBr) in cm-1: 2925, 2855 (CH2 str), 1601 (C=N), 1457 (C=C), 1335 
(SO2 str assym), 1156 (SO2 str sym), 1112 (C-O-C).
 1H NMR (CDCl3, 300 MHz) δ ppm: 1.31-
1.45 (m, 3H), 1.62-1.78 (m, 3H), 1.86-1.91 (m, 2H), 2.13-2.18 (m, 2H), 2.71 (s, 3H), 2.96-3.04 
(m, 1H), 3.20-3.22 (q, 4H), 3.75 (t, 4H), 7.49 (d, 1H, J = 8.1 Hz), 7.66-7.72 (m, 1H), 8.18 (dd, 
1H, J = 7.8 Hz ), 8.49  (s, 1H). 13C NMR (100 MHz, CDCl3) δ ppm: 170.5, 162.8, 142.6, 136.1, 
133.4, 130.8, 128.3, 122.7, 66.2, 45.3, 35.3, 30.2, 28.9, 25.4, 20.9. LC/ESI-MS: m/z value; 392 
(M+1). Anal calc. for C19H25N3O4S (391): C 58.29, H 6.44, N  10.73, O 16.35 Found C 58.62, H 
6.46, N 10.77, O 16.41. 
 
 1-Benzhydryl-4-[5-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-methyl-benzenesulfonyl]-piperazine 
(5n). Yield 75%; m.p. 168 oC. FTIR (KBr) in cm-1: 3451 (NH- str piperazine), 2928, 2853 (CH2 
str), 1557 (C=N), 1449 (C=C), 1326 (SO2 str assym), 1156 (SO2 str sym), 1080 (C-O-C).
 1H 
NMR (CDCl3, 300 MHz) δ ppm:
 1.37-1.46 (m, 2H) 1.80-1.91 (m, 3H), 2.05-2.16 (d, 2H), 2.45-
2.48 (t, 4H), 2.70 (m, 3H), 2.95-3.03 (m, 1H) 3.18-3.24 (m, 4H), 4.23 (s, 1H),7.15-7.19 (m, 2H), 
7.21-7.31 (m, 4H), 7.35 (dd, 4H, J = 12.9 Hz), 7.47 (d, 1H, J = 7.8 Hz), 8.17 (d, 1H, J  = 7.8 
Hz), 8.59 (s, 1H). 13C NMR (100 MHz, CDCl3) δ ppm: 170.3, 163.0, 142.3, 141.6, 133.9, 131.1, 
130.0, 127.8, 125.3, 123.8, 122.6, 114.6, 65.8, 50, 35.3, 30.1, 27.9, 25.4, 20.9, 15.3. LC/ESI-
MS: m/z value; 557 (M+1). Anal calc. for C19H25N3O4S (556): C 69.04, H 6.52, N 10.06, O  
8.62 Found C 69.02, H 6.66, N 9.96, O 8.39.  
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       indoline (5j)
       6-nitro indoline (5k)
       indole (5l)
       morpoline(5m)
       1-benzhdryl piperazine(5n)
 
Figure 1. Scheme route of 2,5-disubstituted-1,3,4-oxadiazole derivatives. 
Antibacterial assay 
The newly synthesized compounds were screened for their in vitro antibacterial activity against 
pathogens gram positive: E. coli, S. Aureus; gram negative: P. aeruginosa and B. subtilis at 
various concentrations at 100 µg/mL by using disc diffusion method [33-34]. All the test 
compounds were dissolved in DMSO and cultured in Mueller–Hinton broth (MHB). 6 mm 
diameters of sterile discs were placed in the petri plates, to which appropriate concentrations of 
different synthesized compounds were added. The three triplicates were maintained for each 
plate and were incubated at 37 ºC for 24 h. Amikacin (30 µg) was used as a positive reference 
standard and DMSO as negative control. The diameter of the clear zone around the disc was 
measured and expressed in millimeters as its zone of inhibition. 
 
Antifungal assay 
The antifungal activities of synthetic compounds were evaluated by disc diffusion technique. All 
the compounds are screened in vitro for their antifungal activity against Candida albicans and 
Aspergillus niger. Potato dextrose agar (PDA) was used for fungal cultures. The culture medium 
was inoculated with the fungal strains separately suspended in Potato dextrose broth. The 
synthesized compounds were applied on the sterile disc. Standard antibiotic (ketoconazole 30 
µg) was used as positive control, and fungal plates were incubated at 37 oC for 72 h and 
triplicates were maintained. The diameters of zone of inhibition observed were measured. 
 
In vitro anti-inflammatory activity (BSA assay)  
The synthesized compounds were screened for their in vitro anti-inflammatory activity by using 
albumin denaturation assay by following the procedure reported by Kavitha et al. [35].  
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In vitro anti-diabetic activity (α-amylase assay) 
 
All the synthesized compounds were evaluated for in vitro anti-diabetic activity by α-amylase 




Quantum chemical parameter like dipole moment, EHOMO, ELUMO and energy gap (ΔE), global 
hardness (η), global softness (S), chemical potential (µ), electrophilic index (ω) of the all title 
compounds were fully optimized using density functional theory method by RB3LYP. The 
structure of the all titled compounds were geometrically optimized by functional hybrid 
RB3LYP with electron basis set 6-311++G(2d,p) for the atoms with Gaussian 09 [36]. C log P 
was calculated by Chem draw ultra 8.0.  
 
RESULTS AND DISCUSSION 
Chemistry 
 
All synthesized compounds are confirmed by absorption bands 3080-3150 cm-1 corresponding 
to NH stretching of the amide. The absorption peaks are observed at 2927-2940 cm-1 and 2850-
2862 cm-1 due to aliphatic CH2 stretching. FT-IR stretching vibrations appeared at 1327-1339 
(SO2 asymmetric) and 1150-1162 cm
-1 (SO2 symmetric)
 for all synthesized compound. IR 
stretching bands showed around at 1576 cm-1 (C=N) and 1584 cm-1 (C=C). The stretching 
vibrations are appeared around at 1081 cm-1 (C-O-C) which are present in 1,3,4-oxadiazole ring, 
respectively. 
For NMR spectra, a singlet peak was observed at 2.63-2.78 ppm due to the presence of CH3   
group and also singlet peak appeared at 3.73 ppm for OCH3. The appearance of multiplet at 
2.91-3.10 ppm indicated that the presence of CH (aliphatic) of the synthesized compounds. A 
doublet or multiplet peaks were observed at 6.32-8.12 ppm due to the presence of aromatic and 
heterocyclic protons. The 1H NMR spectra of the sulphonamide derivatives showed most 
downfield singlet signal at 8.32-9.93 ppm for sulphonamide NH proton. 13C NMR spectrum of 
compound 3 was clearly confirmed by the chemical shift at δ 168.5 and δ 163.2 ppm. The 
characteristic peaks for aromatic(C-H) at around δ 132 ppm. The structures of all synthesized 




All the titled compounds were subjected to antibacterial activity against gram positive bacteria 
and gram negative bacteria at concentration of 100 μg/mL by using disc diffusion technique. 
Amikacin was used as reference drug. The zone of inhibition of the synthesized compounds is 
summarized Table 1. From obtained data, all synthesized compounds exhibited moderate to 
better activity against all the concentrations of 100 μg/mL. Compounds 5a, 5b, 5c, 5d, 5f, and 
5g exhibited good activity against B. subtilis and E. coli compared with the standard. 
Furthermore, synthetic compounds 5a, 5f, and 5g were found to be effective against P. 
aeruginosa. For these, compounds were optimized by DFT studies. Compound 5i was inactive 
against most of the bacterial strains. 
  
 Antifungal studies 
 
All synthesized compounds were evaluated for their antifungal activity against Candida 
albicans and Aspergillus nigar at 100 μg/mL with Ketaconazole as standard drug. Compounds 
5a and 5n displayed good activity against the fungai C. albicans. In the novel series, the 
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majority of the synthesized compounds exhibited moderate to good activity against C. albicans 
with the zone of inhibition 9-13 mm. In the case of A. niger, the most of the synthesized 
compounds displayed moderate activity against all tested organisms with the zone of inhibition 
8-10 mm. 
 
Table 1. Zone of inhibition of antimicrobial activities of all synthesized compounds (5a-5n). 
 
Compound code 
Diameter of zone of inhibition in mm 
Gram positive bacteria Gram positive bacteria Antifungal 
SA BS EC PA CA AN 
5a 18 17 15 24 13 - 
5b 10 13 13 11 10 8 
5c 10 12 12 10 11 10 
5d 11 13 13 11 10 8 
5e 11 13 12 11 10 8 
5f 13 14 14 20 10 8 
5g 15 14 16 26 10 8 
5h 8 8 9 10 - 7 
5i - - - 9 - 8 
5j 10 12 10 8 10 8 
5k 10 10 10 - 9 8 
5l 10 12 10 10 10 8 
5m 11 12 8 12 13 9 
5n 10 12 10 10 10 8 
Amikacin 29 28 26 25   
Ketaconazole     20 22 
SA = Staphylococcus aureus ATCC 9144, BS = Bacillus subtilis ATCC 6051, EA = Escherichia coli 
ATCC 25922, PA= Pseudomonas aeruginosa ATCC-2853, CA= Candida albicans  MTCC-227, AN = 
Aspergillus niger MTCC-281. 
 
The results indicated that the presence of halogen, nitro substituted benzene sulfonamide 
with 1,3,4-oxadiazole moiety showed significant antimicrobial activity. (i) It was observed that 
fluoro substituted 1,3,4-oxadiazole derivatives were more active compared to chloro and bromo 
derivatives, followed by derivatives like methoxy, methyl groups respectively [37]. (ii) The 
presence of electron withdrawing groups and electron donating groups in phenyl ring may 
enhance antimicrobial activity of the titled compounds [38]. (iii) Hetero aryl ring (like indole) 
substituted with 1,3,4-oxdiazole moiety enhances the anti-diabetic activity. (iv) Results revealed 
that, most of the tested compounds showed good anti-inflammatory activities, due to the 
presence of hereto substituted aryl ring in the 1,3,4-oxdaizole derivatives.  
 
In vitro anti-inflammatory activity 
 
All the synthesized compounds (5a-n) were evaluated for their in vitro anti-inflammatory 
activity and were carried out using serum albumin denaturation technique with five different 
concentrations such as 50, 100, 200, 400 and 500 µg, respectively. In the series, most of the 
compounds 5b, 5e, 5f and 5l exhibited good activity with IC50 values of 118.2, 110.9, 140.3, and 
140.9 µM. While, synthesized compounds 5c and 5d are more active than drug diclofenac (IC50 
= 156 µM). Compound 5n showed less activity than all other compounds. The resulting data of 
the anti-inflammatory activity of all the synthesized compounds are shown in Figure 2.  
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Figure 2. Anti- inflammatory activities of tested compounds (
 
In vitro antidiabetic activity 
 
In this present study, all synthesized compounds were screened against α
Synthesized compounds were checked with five different concentrations 50
1000 µm. The compounds 5j
values of (6.23, 6.59, 2.34 and 7.15) µM than standard drug acarbose (IC
Furthermore, the remaining compounds have shown moderate to weak activities (IC
µM). The resulting bar graph representation of anti
shown in Figure 3.  
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Quantum chemical parameters such as HOMO, LUMO, energy gap (ΔE), global hardness, and 
electrophilicity index are calculated and shown in Table 2. HOMO and LUMO orbital are 
important orbital in the molecule because that involving chemical reaction [39-41].  
 
Table 2. Quantum chemical descriptor for synthesized compounds (5a-5n) calculated using RB3LYP/6-
311G (d, p) and values in a.u. 
 
Compound E HOMO ELUMO ΔE µ μ (D) η S ω  C log P 
5a -0.19027 -0.1662 -0.02407 -0.17823 7.2166 0.01203 41.54 1.3200 4.364 
5b -0.20236 -0.15489 -0.04747 -0.17862 3.4698 0.02373 21.06 0.6721 4.696 
5c -0.20922 -0.15868 -0.05054 -0.18375 3.6699 0.02527 19.78 0.6608 4.131 
5d -0.17862 -0.12222 -0.05648 -0.15042 3.5890 0.02824 17.70 0.4006 4.934 
5e -0.17953 -0.12358 -0.05595 -0.15156 4.0261 0.02798 17.87 0.4105 5.084 
5f -0.18021 -0.07526 -0.10495 -0.12773 7.8339 0.05247 9.528 0.15545 4.171 
5g -0.18804 -0.08381 -0.10423 -0.13592 5.643 0.05211 9.594 0.17721 4.516 
5h -0.21128 -0.14594 -0.06534 -0.17861 4.6412 0.03267 15.30 0.48823 5.371 
5i -0. 22455 -0.14562 -0.07894 -0.18508 5.0767 0.03947 12.66 0.43395 3.141 
5j -0.22943 -0.06082 -0.16861 -0.14512 6.3294 0.08305 5.93 0.12490 4.393 
5k -0.14443 -0.06118 -0.0832 -0.10280 6.456 0.04160 12.01 0.12702 4.502 
5l -0.14171 -0.05664 -0.0857 -0.09917 6.3939 0.04285 11.66 0.11475 4.969 
5m -0.1259 -0.07874 -0.04716 -0.10232 2.3943 0.02358 21.20 0.22199 2.625 
          5n -0.18287 -0.05918 -0.12369 -0.12102 6.4525 0.06185 8.084 0.11840 6.256 
 
Compound 5a has the highest LUMO and HOMO energy gap and compound 5j has lowest 
value among all the synthesized compounds. The HOMO-LUMO energy gap increases with 
increases chemical reactivity of the molecules and also increases in activity against all the tested 
microorganisms. The global hardness (η) is one of the properties of the molecule use to measure 
the intensity of chemical reactivity. The decreasing order lower values of η for these compounds 
are 5c > 5b > 5m > 5a. The lowest chemical hardness for the compound has less stable and 
more reactive. Global softness (S) is the reciprocal of the hardness and is related to chemical 
reactivity and energy gap of the molecules. Therefore, compound 5a is more reactive than others 
synthesized compounds. Electrophilic index (ω = µ2/2η) is calculated by chemical potential and 
chemical hardness. It is used to measure the propensity or capacity of the species to accept the 
electrons. The results of electrophilic index indicate that compound 5l acts as a strongest 
nucleophile and 5a acts as a strongest an electrophile.  
Lipophilicity, chemical reactivity, energy gap have significant properties on bioactive of the 
compounds. In general, the chemically reactive compounds are less suitable for the biological 
activity. Apart from this, synthesized compounds have the lower values of C log P showed good 
antimicrobial activities. It was explained by well-known lipophlic compounds are favorable for 
being delivered binding site to the organism. Compound 5m has lower value (2.325) than all 
other synthesized compounds and were calculated using Chem Draw software 8.0. It could be 
concluded that halogen, OCH3 and CH3 substituted phenyl group which increase the stability of 
the compound. This is confirmed by DFT studies which give better microbial activity with their 
derivatives.  
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In this study, we have synthesized a novel series of 1,3,4-oxadaizole and evaluated for their in 
vitro antimicrobial activity, anti-inflammatory, antidiabetic activities. The in vitro antimicrobial 
activity of these tested compounds showed moderate to good activity. Compound 5l is more 
active than standard acarbose. Results showed that the majority of the synthesized compounds 
exhibited excellent anti-inflammatory activity and it further considered for vivo assays for 
finding leading anti-inflammatory agents. All the synthesized compounds were optimized by 
density functional theory (DFT) studies indicated that zone of the inhibition of compounds 
(experimental) which is correlated with quantum parameters (theoretically) and gave useful 
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